About all

Blastomycosis treatment. Comprehensive Guide to Blastomycosis: Diagnosis, Treatment, and Prevention

by alexxlab

What are the clinical manifestations of blastomycosis. How is blastomycosis diagnosed and treated. What are the risk factors for developing blastomycosis. How can blastomycosis be prevented. What is the epidemiology of blastomycosis in North America. How does blastomycosis affect immunocompromised individuals. What are the latest research developments in blastomycosis treatment.

Содержание

Understanding Blastomycosis: A Fungal Infection

Blastomycosis is a potentially serious fungal infection caused by the dimorphic fungus Blastomyces dermatitidis and the recently identified species Blastomyces gilcristii. This infection primarily affects the lungs but can disseminate to other parts of the body, including the skin, bones, and central nervous system. Blastomycosis is endemic to certain regions of North America, particularly in areas surrounding the Ohio and Mississippi River valleys, the Great Lakes, and the St. Lawrence River.

The fungus responsible for blastomycosis thrives in moist soil rich in organic matter, often found near waterways. Infection typically occurs when individuals inhale fungal spores present in the environment. While blastomycosis can affect anyone, certain groups are at higher risk, including those with weakened immune systems, outdoor workers, and individuals participating in activities that disturb soil.

Clinical Manifestations of Blastomycosis

The clinical presentation of blastomycosis can vary widely, ranging from asymptomatic infections to severe, life-threatening disease. Common symptoms include:

  • Fever
  • Cough (which may be dry or productive)
  • Chest pain
  • Shortness of breath
  • Fatigue
  • Weight loss
  • Night sweats

In cases of disseminated disease, additional symptoms may include:

  • Skin lesions (often verrucous or ulcerative)
  • Bone pain
  • Joint pain
  • Headaches (in cases of central nervous system involvement)
  • Vision changes

Diagnosis and Treatment Approaches for Blastomycosis

Diagnosing blastomycosis can be challenging due to its varied presentation and similarity to other respiratory infections. Physicians typically employ a combination of clinical assessment, imaging studies, and laboratory tests to confirm the diagnosis.

Diagnostic Methods

How is blastomycosis diagnosed? The following methods are commonly used:

  1. Microscopic examination: Direct visualization of the characteristic broad-based budding yeast forms in clinical specimens.
  2. Culture: Isolation of B. dermatitidis from clinical samples, which remains the gold standard for diagnosis.
  3. Antigen detection: Urine antigen testing can be useful, especially in immunocompromised patients.
  4. Serology: Detection of antibodies against B. dermatitidis, although cross-reactivity with other fungi can occur.
  5. Molecular methods: PCR-based techniques for rapid identification of Blastomyces species.
  6. Imaging: Chest X-rays and CT scans to assess lung involvement and potential dissemination.

Treatment Strategies

What is the recommended treatment for blastomycosis? Treatment depends on the severity of the infection and the patient’s overall health status. The primary treatment options include:

  • Itraconazole: First-line treatment for mild to moderate pulmonary and disseminated blastomycosis.
  • Amphotericin B: Reserved for severe or life-threatening cases, central nervous system involvement, or in patients who cannot tolerate azoles.
  • Fluconazole: An alternative for patients who cannot tolerate itraconazole, although it may be less effective.
  • Voriconazole or Posaconazole: Newer azoles that may be used in refractory cases or as alternatives to itraconazole.

Treatment duration typically ranges from 6 to 12 months, depending on disease severity and clinical response. Close monitoring of liver function and drug levels is essential during treatment.

Epidemiology and Geographic Distribution of Blastomycosis

Blastomycosis is primarily endemic to North America, with the highest incidence rates reported in the United States and Canada. The disease exhibits a distinct geographic distribution, with notable hotspots in specific regions.

United States

In the United States, blastomycosis is most commonly found in:

  • The Ohio and Mississippi River valleys
  • The Great Lakes region, particularly Wisconsin and Minnesota
  • Southeastern states, including Arkansas, Kentucky, and Tennessee

Wisconsin has consistently reported some of the highest incidence rates, with outbreaks occurring periodically. A large community outbreak in 2010 affected 55 people, highlighting the potential for significant local transmission.

Canada

In Canada, blastomycosis is primarily reported in:

  • Ontario, particularly in the Kenora region
  • Manitoba
  • Quebec, along the St. Lawrence River

The incidence of blastomycosis in these areas can be substantial, with rates in some endemic regions comparable to or exceeding those seen in the United States.

Risk Factors and Vulnerable Populations

While anyone can contract blastomycosis, certain factors increase the risk of infection or severe disease. Understanding these risk factors is crucial for prevention and early diagnosis.

Environmental and Occupational Factors

What activities increase the risk of blastomycosis exposure? Individuals at higher risk include:

  • Outdoor workers (e.g., forestry workers, construction workers)
  • Hunters and campers
  • Individuals involved in activities that disturb soil (e.g., landscaping, excavation)

Host Factors

Certain populations are more vulnerable to severe or disseminated blastomycosis:

  • Immunocompromised individuals (e.g., HIV/AIDS patients, organ transplant recipients)
  • Patients receiving immunosuppressive therapies (e.g., TNF-α inhibitors)
  • Individuals with chronic lung diseases
  • Pregnant women
  • Elderly individuals

Studies have shown that immunocompromised patients, particularly those with HIV/AIDS or solid organ transplants, are at increased risk of severe and disseminated blastomycosis. These patients may require more aggressive treatment and prolonged therapy.

Prevention Strategies and Public Health Measures

Preventing blastomycosis poses challenges due to the environmental nature of the pathogen. However, several strategies can help reduce the risk of infection, especially in endemic areas.

Individual Prevention Measures

How can individuals protect themselves from blastomycosis? Consider the following precautions:

  • Wear protective equipment (e.g., masks, gloves) when engaging in activities that disturb soil in endemic areas
  • Avoid areas with known outbreaks or high incidence rates
  • Be aware of symptoms and seek medical attention promptly if they occur
  • For immunocompromised individuals, consider antifungal prophylaxis when living in or visiting highly endemic areas

Public Health Initiatives

Public health efforts to control blastomycosis include:

  • Surveillance and reporting systems to track cases and identify outbreaks
  • Education programs for healthcare providers and the public about the disease
  • Environmental sampling and monitoring in high-risk areas
  • Research into potential environmental control measures

These initiatives aim to improve early detection, enhance treatment outcomes, and reduce the overall burden of blastomycosis in endemic regions.

Blastomycosis in Immunocompromised Patients

Immunocompromised individuals face unique challenges when it comes to blastomycosis. The disease can progress more rapidly and be more difficult to diagnose and treat in this population.

Specific Considerations

What are the key considerations for blastomycosis in immunocompromised patients?

  • Higher risk of severe and disseminated disease
  • Atypical clinical presentations, making diagnosis challenging
  • Increased likelihood of treatment failure or relapse
  • Potential drug interactions with other medications
  • Need for prolonged antifungal therapy

Management Strategies

Managing blastomycosis in immunocompromised patients often requires:

  • More aggressive initial treatment, typically with amphotericin B
  • Longer duration of therapy
  • Close monitoring for drug toxicities and treatment response
  • Consideration of lifelong suppressive therapy in select cases
  • Multidisciplinary approach involving infectious disease specialists, transplant physicians, and other relevant specialists

Research has shown that early diagnosis and prompt, appropriate treatment are crucial for improving outcomes in this vulnerable population.

Recent Advances and Future Directions in Blastomycosis Research

The field of blastomycosis research continues to evolve, with recent advances improving our understanding of the disease and paving the way for new diagnostic and treatment approaches.

Molecular Biology and Genetics

Recent genetic studies have led to the identification of a new species, Blastomyces gilcristii, which was previously thought to be a genetic variant of B. dermatitidis. This discovery has implications for understanding the epidemiology and potentially the clinical aspects of blastomycosis.

Diagnostic Innovations

What are the latest developments in blastomycosis diagnostics? Researchers are focusing on:

  • Improved molecular diagnostic techniques for rapid and accurate identification of Blastomyces species
  • Development of more sensitive and specific antigen detection assays
  • Exploration of biomarkers for disease progression and treatment response

Treatment Advancements

Ongoing research in blastomycosis treatment includes:

  • Evaluation of newer antifungal agents and combination therapies
  • Investigation of immunotherapeutic approaches
  • Development of targeted therapies based on fungal virulence factors

Vaccine Development

While no vaccine is currently available for blastomycosis, research into potential vaccine candidates is ongoing. These efforts focus on identifying protective antigens and developing effective vaccine delivery systems.

As research progresses, the hope is that these advancements will lead to improved prevention, diagnosis, and treatment strategies for blastomycosis, ultimately reducing the burden of this challenging fungal infection.

Clinical manifestations and treatment of blastomycosis

1. Brown EM, McTaggart LR, Zhang SX, Low DE, Stevens DA, Richardson SE. Phylogenetic analysis reveals a cryptic species Blastomyces gilcristii, sp. nov. within the human pathogenic fungus. Blastomyces dermatitidis PLoS ONE. 2013;8(3):e59237. [PMC free article] [PubMed] [Google Scholar]

2. Wolf PL, Russel B, Shimoda A, editors. Section X: Identification of Dimorphic Fungi Causing Systemic Mycosis. New York: John Wiley & Sons; 1975. Practical Clinical Microbiology and Mycology: Techniques and Interpretations; pp. 486–488. [Google Scholar]

3. Wu SJ, Valyi-Nagy T, Engelhard HH, et al. Secondary intracerebral blastomycosis with giant yeast forms. Mycopathologia. 2005;160(3):253–725. [PubMed] [Google Scholar]

4. Klein BS, Vergeront JM, Weeks RJ, et al. Isolation of Blastomyces dermatitidis in soil associated with a large outbreak of blastomycosis in Wisconsin. N Engl J Med. 1986;314(9):529–534. [PubMed] [Google Scholar]

5. Gauthier G, Klein BS. Chapter 198 – Blastomycosis. In: Cherry JD, Harrison GJ, editors. Feigin and Cherry’s Textbook of Pediatric Infectious Disease. Seventh. Philadelphia (PA): Elsevier Saunders; 2014. pp. 2723–2743. [Google Scholar]

6. Baily GG, Robertson VJ, Neill P, Garrido P, Levy LF. Blastomycosis in Africa: clinical features, diagnosis, and treatment. Rev Infect Dis. 1991;13(5):1005–1008. [PubMed] [Google Scholar]

7. Randhawa HS, Chowdhary A, Kathuria S, et al. Blastomycosis in India; report of an imported case and current status. Med Mycol. 2013;51(2):185–192. [PubMed] [Google Scholar]

8. Carlos WG, Rose AS, Wheat LJ, et al. Blastomycosis in Indiana: digging up more cases. Chest. 2010;138(6):1377–1382. [PubMed] [Google Scholar]

9. Crampton TL, Light RB, Berg GM, et al. Epidemiology and clinical spectrum of blastomycosis diagnosed at Manitoba hospitals. Clin Infect Dis. 2002;34(10):1310–1316. [PubMed] [Google Scholar]

10. Centers for Disease Control and Prevention (CDC) Blastomycosis – Wisconsin, 1986–1995. MMWR Morb Mortal Wkly Rep. 1996;45(28):601–603. [PubMed] [Google Scholar]

11. Furcolow ML, Chick EW, Busey JP, Menges RW. Prevalence and incidence studies of human and canine blastomycosis. 1. Cases in the United Stated, 1885–1968. Am Rev Respir Dis. 1970;102(1):60–67. [PubMed] [Google Scholar]

12. Baumgardner DJ, Buggy BP, Mattson BJ, Burdick JS, Ludwig D. Epidemiology of blastomycosis in a region of high endemicity in north central Wisconsin. Clin Infect Dis. 1992;15(4):629–635. [PubMed] [Google Scholar]

13. Dwight PJ, Naus M, Sarsfield P, Limerick B. An outbreak of human blastomycosis: the epidemiology of blastomycosis in the Kenora catchment region of Ontario, Canada. Can Commun Dis Rep. 2000;26(10):82–91. [PubMed] [Google Scholar]

14. Lowry PW, Kelso KY, McFarland LM. Blastomycosis in Washington Parish, Louisiana 1976–1985. Am J Epidemiology. 1989;130(1):151–159. [PubMed] [Google Scholar]

15. Chapman SW, Lin AC, Hendricks KA, et al. Endemic blastomycosis in Mississippi: epidemiologic and clinical studies. Semin Respir Infect. 1997;12(3):219–228. [PubMed] [Google Scholar]

16. Seitz AE, Younes N, Steiner CA, Prevots DR. Incidence and trends of blastomycosis-associated hospitalizations in the United States. PLoS ONE. 2014;9(8):e105466. [PMC free article] [PubMed] [Google Scholar]

17. Morris S, Brophy J, Richardson SE, et al. Blastomycosis in Ontario, 1994–2003. Emerg Infect Dis. 2006;12:274–279. [PMC free article] [PubMed] [Google Scholar]

18. Gauthier GM, Safdar N, Klein BS, Andes Dr. Blastomycosis in solid organ transplant recipients. Transpl Infect Dis. 2007;9(4):310–317. [PubMed] [Google Scholar]

19. Grim SA, Proria L, Miller R, et al. A multicenter study of histoplasmosis and blastomycosis after solid organ transplantation. Transpl Infect Dis. 2012;14(1):17–23. [PubMed] [Google Scholar]

20. Smith JA, Kauffman CA. Endemic fungal infections in patients receiving tumour necrosis factor-alpha inhibitor therapy. Drugs. 2009;69(11):1403–1415. [PubMed] [Google Scholar]

21. Pappas PG. Blastomycosis in the immunocompromised patient. Semin Respir Infect. 1997;12(3):243–251. [PubMed] [Google Scholar]

22. Pappas PG, Pottage JC, Powderly WG, et al. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med. 1992;116(10):847–853. [PubMed] [Google Scholar]

23. Roy M, Benedict K, Deak E, Kirby M, et al. A Large Community Outbreak of Blastomycosis in Wisconsin with Geographic and Ethnic Clustering. Clin Infect Dis. 2013;57(5):655–662. [PMC free article] [PubMed] [Google Scholar]

24. Gauthier GM, Klein BS. Insights into fungal morphogenesis and immune evasion. Microbe. 2008;3:416–423. [PMC free article] [PubMed] [Google Scholar]

25. Sterkel AK, Mettelman R, Wüthrich M, Klein BS. The unappreciated intracellular lifestyle of Blastomyces dermatitidis. J Immunol. 2015;194(4):1796–1805. [PMC free article] [PubMed] [Google Scholar]

26. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect Immun. 2009;77(1):120–127. [PMC free article] [PubMed] [Google Scholar]

27. Nemecek JC, Wüthrich M, Klein BS. Global control of dimorphism and virulence in fungi. Science. 2006;312(5773):583–588. [PubMed] [Google Scholar]

28. Brandhorst TT, Wüthrich M, Warner T, Klein B. Targeted gene disruption reveals an adhesion indispensable for pathogenicity of Blastomyces dermatitidis. J Exp Med. 1999;189(8):1207–1216. [PMC free article] [PubMed] [Google Scholar]

29. Brandhorst TT, Roy R, Wüthrich M, et al. Structure and function of a fungal adhesion that binds heparin and mimics thrombospondin-1 by blocking T cell activation and effector function. PLoS Pathog. 2013;9(7):e1003464. [PMC free article] [PubMed] [Google Scholar]

30. Finkel-Jimenez B, Wüthrich M, Klein BS. BAD1, an essential virulence factor of Blastomyces dermatitidis, suppress hosts TNF-α production through TGF-β-dependent and –independent mechanisms. J Immunol. 2002;168(11):5746–5755. [PubMed] [Google Scholar]

31. Finkel-Jimenez, Wüthrich M, Brandhorst T, Klein BS. The WI-1 adhesin blocks phagocyte TNF-α production, imparting pathogenicity on Blastomyces dermatitidis. J Immunol. 2001;166(4):2665–2673. [PubMed] [Google Scholar]

32. Muñoz JF, Gauthier GM, Desjardins CA, et al. The dynamic genome and transcriptome of the human fungal pathogen Blastomyces and close relative Emmonsia. PLoS Pathog. 2015;11(10):e1005493. [PMC free article] [PubMed] [Google Scholar]

33. Kanetsuna F, Carbonell LM. Cell wall composition of the yeast-like and mycelial forms of Blastomyces dermatitidis. J Bacteriol. 1971;106(3):946–948. [PMC free article] [PubMed] [Google Scholar]

34. Marty AJ, Broman AT, Zarnowski R, et al. Fungal morphology, iron homeostasis, and lipid metabolism regulated by a GATA transcription factor in Blastomyces dermatitidis. PLoS Pathog. 2015;11(6):31004959. [PMC free article] [PubMed] [Google Scholar]

35. Gilmore SA, Naseem S, Konopka JB, Sil A. N-acetylglucosamine (G1cNAc) triggers a rapid temperature-responsive morphogenetic program in thermally dimorphic fungi. PLoS Genet. 2013;9:e1003799. [PMC free article] [PubMed] [Google Scholar]

36. Sugar AM, Picard M, Wagner R, Kornfeld H. Interactions between human bronchoalveolar macrophages and Blastomyces dermatitidis conidia: demonstration of fungicial and fungistatic effects. J Infect Dis. 1995;171(6):1559–1562. [PubMed] [Google Scholar]

37. Rocco NM, Carmen JC, Klein BS. Blastomyces dermatitidis yeast cells inhibit nitric oxide production by alveolar macrophage inducible nitric oxide synthase. Infect Immun. 2001;79(6):2385–95. [PMC free article] [PubMed] [Google Scholar]

38. Klein BS, Bradsher RW, Vergeront JM, Davis JP. Development of long-term specific cellular immunity after acute Blastomyces dermatitidis infection: assessments following a large point source outbreak in Wisconsin. J Infect Dis. 1990;151(1):97–101. [PubMed] [Google Scholar]

39. Lemos LB, Baliga M, Guo M. Blastomycosis: The great pretender can also be an opportunist. Initial clinical diagnosis and underlying disease in 123 patients. Ann Diagn Pathol. 2002;6(3):194–203. [PubMed] [Google Scholar]

40. Larson DM, Eckman MR, Alber RL, Goldschmidt VG. Primary cutaneous (inoculation) blastomycosis: an occupational hazard to pathologist. Am J Clinc Pathol. 1983;79(2):253–255. [PubMed] [Google Scholar]

41. Klein BS, Vergeront JM, Kaufman L, et al. Serologic tests for blastomycosis: assessments during a large point-source outbreak in Wisconsin. J Infect Dis. 1987;155(2):262–268. [PubMed] [Google Scholar]

42. Chapman SW, Dismukes WI, Proia LA, et al.Infectious Diseases Society of America Clinical practice guidelines for the management of blastomycosis: 2008 updated by the Infectious Disease Society of America. Clin Infect Dis. 2008;46(12):1801–1811. [PubMed] [Google Scholar]

43. Limper AH, Knox KS, Sarosi GA, et al. An Official American Thoracic Society Statement: Treatment of Fungal Infections in Adult Pulmonary and Critical Care patients. Am J Respir Crit Care Med. 2011;183:96–128. [PubMed] [Google Scholar]

44. Fanella S, Skinner S, Trepnman E, Embil JM. Blastomycosis in children and adolescents: a 30-year experience from Manitoba. Med Mycol. 2011;49(6):627–32. [PubMed] [Google Scholar]

45. Lemos LB, Baliga M, Guo M. Acute respiratory distress syndrome and blastomycosis: presentation of nine cases and review of the literature. Ann Diagn Pathol. 2001;5(1):1–9. [PubMed] [Google Scholar]

46. Vasquez JE, Mehta JB, Agrawal R, et al. Chest. 1998;114(2):436–443. [PubMed] [Google Scholar]

47. Meyer KC, McManus EJ, Maki DG. Overwhelming pulmonary blastomycosis associated with the adult respiratory distress syndrome. N Engl J Med. 1993;329(17):1231–1236. [PubMed] [Google Scholar]

48. Smith JA, Riddell J, IV, Kauffman CA. Cutaneous manifestations of endemic mycoses. Curr Infect Dis Rep. 2013;15(5):440–449. [PubMed] [Google Scholar]

49. Saccente M, Woods GL. Clinical and laboratory update on blastomycosis. Clin Microbiol Rev. 2010;23(2):367–381. [PMC free article] [PubMed] [Google Scholar]

50. Saucier J, Gauthier G. Photo quiz. Verrucous lesions and ectropion in an immunocompetent individual. Clin Infect Dis. 2012;55(10):1390–1391. 1426–1428. [PubMed] [Google Scholar]

51. Reder PA, Neel HB. Blastomycosis in otolaryngology: review of a large series. Laryngoscope. 1993;103(1 Pt 1):53–58. [PubMed] [Google Scholar]

52. Pariseau B, Lucarelli MJ, Appen RE. A concise history of ophthalmic blastomycosis. Ophthalmology. 2007;114(11):e27–32. [PubMed] [Google Scholar]

53. Jain R, Sing K, Lamzabi I, Harbhajanka A, Gattuso P, Reddy BV. Blastomycosis of the bone: a clinicopathologic study. Am J Clin Pathol. 2014;142(5):609–616. [PubMed] [Google Scholar]

54. Saccente M, Abernathy RS, Pappas PG, Shah HR, Bradsher RW. Vertebral blastomycosis with paravertebral abscess: report of eight cases and review of the literature. Clinc Infect Dis. 1998;26(2):413–418. [PubMed] [Google Scholar]

55. Seo R, Oyasu R, Schaeffer A. Blastomycosis of the epididymis and prostate. Urology. 1997;50(6):980–982. [PubMed] [Google Scholar]

56. Barocas JA, Gauthier GM. Peritonitis caused by Blastomyces dermatitidis in a kidney transplant recipient: case report and literature review. Transpl Infect Dis. 2014;16(4):634–641. [PubMed] [Google Scholar]

57. Farber E, Leahy M, Meadows T. Endometrial Blastomycosis Acquired by Sexual Contact. Obstetrics & Gynecology. 1968;32(2):195–199. [PubMed] [Google Scholar]

58. Bariola JR, Perry P, Pappas PG, et al. Blastomycosis of the central nervous system: a multicenter review of diagnosis and treatment in the modern era. Clin Infect Dis. 2010;50(6):797–804. [PubMed] [Google Scholar]

59. Smith RJ, Boos MD, Burnham JM, McKay EM, Kim J, et al. Atypical cutaneous blastomycosis in a child with juvenile idiopathic arthritis on infliximab. Pediatrics. 2015;136(5):e1386–1389. [PubMed] [Google Scholar]

60. MacDonald D, Alguire PC. Adult respiratory distress syndrome due to blastomycosis during pregnancy. Chest. 1990;98(6):1527–1528. [PubMed] [Google Scholar]

61. Maxson S, Miller SF, Tryka AF, et al. Perinatal blastomycosis: a review. Pediatr Infect Dis J. 1992;11(9):760–763. [PubMed] [Google Scholar]

62. Watts EA, Gard PD, Tuthill SW. First reported case of intrauterine transmission of blastomycosis. Pediatr Infect Dis J. 1983;2(4):308–310. [PubMed] [Google Scholar]

63. Lemos LB, Soofi M, Amir E. Blastomycosis and pregnancy. Ann Diagn Pathol. 2002;6(4):211–215. [PubMed] [Google Scholar]

64. Sarosi GA, Eckman MR, Davies SF, et al. Canine blastomycosis as a harbinger of human disease. Ann Intern Med. 1979;91(5):733–735. [PubMed] [Google Scholar]

65. Patel AJ, Gattuso P, Reddy VB. Diagnosis of blastomycosis in surgical pathology and cytopathology: correlation with microbiologic culture. Am J Surg Pathol. 2010;34(2):256–261. [PubMed] [Google Scholar]

66. Martynowicz MA, Prakash UB. Pulmonary blastomycosis: an appraisal of diagnostic techniques. Chest. 2002;121(3):768–773. [PubMed] [Google Scholar]

67. Richer SM, Smedema ML, Durkin MM, et al. Development of a highly sensitive and specific blastomycosis antibody enzyme immunoassay using Blastomyces dermatitidis surface protein BAD-1. Clin Vaccine Immunol. 2014;21(2):143–146. [PMC free article] [PubMed] [Google Scholar]

68. Durkin M, Witt J, Lemonte A, Wehat B, Connolly P. Antigen assay with the potential to aid in diagnosis of blastomycosis. J Clin Microbiol. 2004;42:4873–4875. [PMC free article] [PubMed] [Google Scholar]

69. Bariola JR, Hage CA, Durkin M, et al. Detection of Blastomyces dermatitidis antigen in patients with newly diagnosed blastomycosis. Diagn Msicrobiol Infect Dis. 2011;69(2):143–146. [PubMed] [Google Scholar]

70. Connolly P, Hage CA, Bariola JR, et al. Blastomyces dermatitidis antigen detection by quantitative enzyme immunoassay. Clin Vaccine Immunol. 2012;19(1):53–56. [PMC free article] [PubMed] [Google Scholar]

71. Frost HM, Novicki TJ. Blastomyces antigen detection for diagnosis and management of blastomycosis. J Clin Microbiol. 2015;53(11):3660–3662. [PMC free article] [PubMed] [Google Scholar]

72. Fang W, Washington L, Kumar N. Imaging manifestations of blastomycosis: a pulmonary infection with potential dissemination. Radiographics. 2007;27(3):641–655. [PubMed] [Google Scholar]

73. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357(9270):1766–1777. [PubMed] [Google Scholar]

74. De Santis M, Di Gianantonio E, Cesari E, Ambrosini G, Straface G, Clementi M. First-trimester itraconazole exposure and pregnancy outcome: a prospective cohort study of women contacting teratology information services in Italy. Drug Saf. 2009;32(3):239–244. [PubMed] [Google Scholar]

75. Pursley TJ, Blomquist IK, Abraham, Andersen HF, Bartley JA. Fluconazole-induced congential anomalies in three infants. Clin Infect Dis. 1996;22(2):336–340. [PubMed] [Google Scholar]

76. Girois SB, Chapuis F, Decullier E, Revol GB. Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clinc Microbiol Infect Dis. 2005;24(2):119–130. [PubMed] [Google Scholar]

77. Ta M, Flowers SA, Rogers PD. The role of voriconazole in the treatment of central nervous system blastomycosis. Ann Pharmacother. 2009;43(10):1696–1700. [PubMed] [Google Scholar]

78. Proia LA, Harnisch DO. Successful use of posaconazole for treatment of blastomycosis. Antimicrob Agents Chemother. 2012;56(7):4029. [PMC free article] [PubMed] [Google Scholar]

79. Gonzalez GM. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol. 2009;47(1):71–76. [PubMed] [Google Scholar]

80. Andes D, Pascual A, Marchetti O. Antifungal therapeutic drug monitoring: established and emerging indications. Antimicrobial Agents Chemother. 2009;53(1):24–34. [PMC free article] [PubMed] [Google Scholar]

81. Lahm T, Neese S, Thornburg AT, Ober MD, Sarosi GA, Hage CA. Corticosteroids for blastomycosis-induced ARDS: a report of two patients and review of the literature. Chest. 2008;133(6):1478–1480. [PubMed] [Google Scholar]

82. Plamondon M, Lamontagne F, Allard C, Pepin J. Corticosteroids as adjunctive therapy in severe blastomycosis-induced acute respiratory distress syndrome in an immunosuppressed patient. Clin Infect Dis. 2010;51(1):e1–e3. [PubMed] [Google Scholar]

83. Schwartz IS, Embil JM, Sharma A, Goulet S, Light RB. Management and outcome of acute respiratory distress syndrome caused by blastomyosis: a retrospective case series. Medicine. 2016;95(18):e3538. [PMC free article] [PubMed] [Google Scholar]

About Blastomycosis – MN Dept. of Health

Topic Menu

Blastomycosis

  • Blastomycosis Home
  • About Blastomycosis
  • Statistics and Maps
  • For Health Professionals

Blastomycosis

  • Blastomycosis Home
  • About Blastomycosis
  • Statistics and Maps
  • For Health Professionals

Blastomycosis is a rare fungal infection usually acquired by breathing in the spores of the fungi Blastomyces dermatitidis or Blastomyces gilchristii. These fungi can be found in moist soils, particularly in wooded areas and along waterways. Blastomycosis occurs most often in people living in Ontario, Manitoba, and the south-central, south-eastern, and the mid-western United States. In Minnesota, blastomycosis is most common in northeastern counties, but can occur throughout the state.

In addition to surveillance for cases in humans, the Minnesota Department of Health and the Board of Animal Health also track blastomycosis cases in animals. This allows us to more accurately outline areas in the state where the disease is found. More animals are affected each year than humans, and the location where the animal was exposed to the fungus is often identified more easily.

On this page:
Transmission
Symptoms
Duration of Illness
Diagnosis
Treatment
Prevention
Fact Sheet

Transmission

  • Blastomycosis is usually caused by inhaling airborne spores from contaminated soil into the lungs. Spores are more likely to be airborne after contaminated soil is disturbed by activities such as excavation, construction, digging, or wood clearing.
  • Very rarely, the fungus can infect an open skin wound and cause infection in just that area of the body.
  • Blastomycosis is not spread person-to-person or animal-to-person.

Symptoms

  • Symptoms of blastomycosis may include:
    • Cough, or cough with blood
    • Fever
    • Shortness of breath
    • Chills and/or night sweats
    • Fatigue
    • Weight loss and poor appetite
    • Joint or bone pain
    • Back or chest pain
    • Skin sores that don’t heal
  • Many patients are first diagnosed with bacterial pneumonia because the symptoms are similar. 

The time between exposure to the spores and when symptoms develop varies widely, ranging from 21 to 100 days. The signs and symptoms of blastomycosis vary among individuals. About 50% of infections are asymptomatic (person does not develop any symptoms or disease) or are mild and resolve without treatment. Some patients develop a chronic lung infection or the disease can spread to other areas of the body (skin, bones, central nervous system, or genitourinary system).

Duration of Illness

  • The duration of illness caused by blastomycosis varies greatly between patients.

Diagnosis

  • Blastomycosis may be diagnosed by:
    • Culture (Blastomyces species can be isolated from saliva, respiratory samples, lung biopsies, skin, or other infected tissues)
    • Cytology smear (direct microscopic identification of broad-based budding yeast)
    • Histopathology of surgical biopsies
    • Urine antigen test or serum antigen test
    • Serum antibody test (less reliable)
  • Your doctor may also ask about your travel history, outdoor activities, or the environment around your home to help determine if you might have been exposed to Blastomyces spores.  

Treatment

  • Blastomycosis can be treated with anti-fungal medications, which are usually continued for at least 6 months.
  • Antibiotics designed for bacteria do not work against blastomycosis.
  • Specific questions about treatment should be discussed with your health care provider.

Prevention

  • Unfortunately, there are no known practical measures for the prevention of blastomycosis.
  • There are currently no methods to test soil for the presence of Blastomyces species.
  • Illness caused by blastomycosis can be minimized by early recognition and appropriate treatment of the disease. Awareness of the disease by both the public and health care providers is the key to early diagnosis.

Fact Sheet

  • Blastomycosis in Minnesota Fact Sheet (PDF)
    Answers to frequently asked questions about blastomycosis.

B01.014.001.001

Primary appointment (examination, consultation) with an infectious disease specialist

3000 ₽

Primary appointment (examination, consultation) with a dermatologist, mycologist

3000 ₽

Online consultation of an infectious disease specialist

3000 ₽

Online consultation with a dermatologist

3000 ₽